Comparison of Multiparameter Flow Cytometry and ClonoSEQ Studies for Precursor B-Lymphoblastic Leukemia Minimal Residual Disease Detection on Bone Marrow Samples

Abstract

general prognostic and therapeutic implication for B-ALL [3]. B-ALL patients with end-induction MRD less than 0.01% had 5-year event-free survival (EFS) higher that those with MRD 0.01%-0.1% [4]. MRD measurements are now standard of care for managing B-ALL patients. Blinatumomab, a bi-specific T-cell engager (BiTE), is approved for use in B-ALL patients in